Evidence map›Paper›PMID 34133968›Full record

ArticleJournal of cardiac failure2021

Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.

Erica M Dillon, Shouzuo D Wei, Deepak K Gupta, Hui Nian, Brooks S Rodibaugh, Katherine N Bachmann, Allen J Naftilan, Lynne W Stevenson, Nancy J Brown

Open access · greenAbstract read
In one paragraph

Article in Journal of cardiac failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Erica M DillonDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: erica.m.dillon@vumc.org.
Shouzuo D WeiDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee.
Deepak K GuptaVanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Hui NianDivision of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Brooks S RodibaughDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee.
Katherine N BachmannVanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University School of Medicine, Nashville, Tennessee; Veterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee; Division of Diabetes, Endocrinology, and Metabolism, Vanderbilt University Medical Center, Nashville, Tennessee.
Allen J NaftilanDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Lynne W StevensonDivision of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Nancy J BrownDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Vanderbilt University Medical Center · USVanderbilt University · USYale University · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
CLINICAL PHARMACOLOGY TRAINING PROGRAMT32GM007569 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Bjorn C Knollmann · 1985 to 2026
$12.4M
Improving Diagnostic Accuracy for Acute Heart FailureR01HL153607 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COLLINS, SEAN PATRICK, GUPTA, DEEPAK · 2021 to 2024
$5.9M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Dietary sodium, inflammation, and salt sensitivity of blood pressureR01HL148661 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALLEN, NORRINA BAI, GUPTA, DEEPAK · 2019 to 2022
$3.1M
Mechanism(s) Underlying Hypotensive Response to ARB/NEP InhibitionR01HL145293 · NHLBI · YALE UNIVERSITY · PI BROWN, NANCY J., STEVENSON, LYNNE W · 2020 to 2024
$3.1M
Tissue Sodium, Inflammation, and Blood Pressure in MESAR01HL133860 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GUPTA, DEEPAK, TITZE, JENS MARC · 2016 to 2019
$2.7M
Vanderbilt Stimulating Access to Research in Residency (V-StARR)R38HL143619 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEBBER, STEVEN A., WILLIAMS, CHRISTOPHER S. · 2018 to 2021
$1.3M
The natriuretic peptide system in African-AmericansK23HL128928 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GUPTA, DEEPAK · 2016 to 2019
$737k
Metabolic Effects of Natriuretic Peptide HormonesIK2CX001678 · VA · VETERANS HEALTH ADMINISTRATION · PI BACHMANN, KATHERINE NEUBECKER · 2018 to 2022
–
CSRD VA IK2 CX001678NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002243NHLBI NIH HHS K23 HL128928NHLBI NIH HHS R01 HL133860NHLBI NIH HHS R01 HL145293NHLBI NIH HHS R01 HL148661NHLBI NIH HHS R01 HL153607NHLBI NIH HHS R38 HL143619NIGMS NIH HHS T32 GM007569NIGMS NIH HHS T32 GM152284
6 · The paper itself

Abstract

backgroundB-type natriuretic peptide (BNP) immunoassays (BNP METHODS AND

resultsWe developed a MS assay with immediate protease inhibition to quantify BNP1-32 over a linear range, using labeled recombinant BNP standard. In 4 healthy volunteers, BNP1-32 by MS (BNP

conclusionsActive BNP measured by MS accounts for only a small amount of BNP measured by immunoassays. Although decreased BNP production was anticipated to be masked by inhibition of degradation, levels of active BNP decreased during chronic sacubitril/valsartan treatment.

Indexed as

Heart FailureNatriuretic Peptide, BrainAminobutyratesBiphenyl CompoundsHumansMass SpectrometryValsartanAminobutyratesBiphenyl CompoundsNatriuretic Peptide, BrainsacubitrilValsartanBNP1-32B-type natriuretic peptide (BNP)heart failuremass spectrometrynatriuretic peptidesneprilysinNT-proBNPsacubitril/valsartan

Identifiers

PMID34133968
PMCPMC8578199
OpenAlexW3167843049

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.